Spoken Alpha
CDT Equity Inc.
CDT Equity Inc. develops pharmaceutical compounds by identifying clinical-stage assets deprioritized by larger drugmakers, applying artificial intelligence and solid-form chemistry to improve drug properties and extend patent life, then licensing them to partners for further development.
CDT Equity Inc is a Healthcare company operating in Biotechnology with a $3.4M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 11, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add CDT, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CDT.
$ curl https://api.spokenalpha.com/v1/companies/CDTFAQ
Spoken Alpha indexes CDT's earnings call transcripts at https://spokenalpha.com/companies/CDT. Each call links to attributed speakers and parsed analyst Q&A. CDT Equity Inc.'s own investor relations page is at https://www.cdtequity.com/investors/.
CDT Equity Inc. (CDT) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-8.71 | — | — | $750.2M | — | — | EODHD |
| Q1 FY2026 | 2026-06-24 | $-99.99 | — | — | $696.4M | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-2314.41 | — | — | $2.72B | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-13.16 | — | — | $698.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-5.46 | — | — | $672.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-1.32 | — | — | $624.9M | — | — | EODHD |
| Q4 FY2024 | 2025-03-27 | $-2.15 | — | — | $1.08B | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $-222396.70 | — | — | $654.9M | — | — | EODHD |
| Q2 FY2024 | 2024-06-29 | $-218668.69 | — | — | $-1.35B | — | — | EODHD |
| Q1 FY2024 | 2024-03-30 | $-145104.50 | — | — | $535.7M | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $-45824.50 | — | — | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-09-29 | $-9208.77 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-06-29 | $-165034.67 | — | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-03-30 | $97628.07 | — | — | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-27 | $0.03 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-06 | $0.01 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.01 | $0.00 | — | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-17 | $-0.02 | $0.00 | — | — | — | — | EODHD |
Source: EODHD. CDT reported actuals as published; sparse fields render as —.